Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.

doi:10.1136/jitc-2021-003027

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.

Journal for immunotherapy of cancer - 1 Feb 2022

West Howard Jack, McCleland Mark, Cappuzzo Federico, Reck Martin, Mok Tony Sk, Jotte Robert M, Nishio Makoto, Kim Eugene, Morris Stefanie, Zou Wei, Shames David, Das Thakur Meghna, Shankar Geetha, Socinski Mark A

Abstract excerpt

BACKGROUND: The efficacy of atezolizumab (A) and/or bevacizumab (B) with carboplatin/paclitaxel (CP) chemotherapy was explored in the phase III, randomized IMpower150 study in patients with non-squamous non-small cell lung cancer (NSCLC) according to KRAS mutations (mKRAS) and co-occurring STK11, KEAP1, or TP53 mutations. METHODS: Mutation status was determined by circulating tumor DNA next-generation sequencing....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Carcinoma, Non-Small-Cell Lung

Share to Kelch-Like ECH-Associated Protein 1

Share to Progression-Free Survival

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35190375
DOI: 10.1136/jitc-2021-003027
PMCID: PMC8862451

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.PMID 35190375Read ↗

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.Semantic proximity Read ↗

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.Semantic proximity Read ↗

<i>STK11</i> and <i>KEAP1</i> Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma CohortSemantic proximity Read ↗

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.Semantic proximity Read ↗

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor.Semantic proximity Read ↗

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.Semantic proximity Read ↗

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.Semantic proximity Read ↗

Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial.Semantic proximity Read ↗

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.